340B Final Rule: An Overview

White Paper written by Robert Blank, Managing Consultant @robert_blank3 With the current focus on the repeal and replacement of the Affordable Care Act (ACA), several other significant elements of healthcare reform are being overlooked. One such regulation is the “340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties,” or 340B Final Rule for short, which was published in the

Read More

The Affordable Care Act: A Review Before Repeal

Written by Robert Blank, Senior Consultant Alliance Life Sciences The Patient Protection and Affordable Care Act of 2010 considerably restructured the way in which healthcare is provided in the United States. Now, as congress plans its “repeal and replacement,”1 it may not be fruitful to speculate about potential superseding laws, but a reexamination of the parameters and impact of the Affordable

Read More

The drug gray market is more common than you think.

Living in today’s high tech-world of sophisticated processes and technology, one would think drug shortages would be a thing of the past, but this is not the case. Many of the drug shortages identified today are linked to quality manufacturing issues, production capacity, and the availability of raw material, all of which contribute to supply disruptions felt by patients and

Read More

Contact Alliance